Agendia MINT I: Multi-Institutional Neo-adjuvant Therapy MammaPrint Project I
Alliance A011202: A Randomized phase III trial comparing axillary lymph node dissection to axillary radiation in Breast Cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neo-adjuvant chemotherapy
NSABP B-51: A Randomized Phase III clinical trial evaluating post-mastectomy chestwall and regional nodal XRTand post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy (Adjuvant)
NSABP B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating the Role of Post-mastectomy Chest Wall and Regional Nodal XRT and Post-lumpectomy Regional Nodal XRT in Patients with Documented Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
TME Neo-Adjuvant Breast Registry (The NEAT Registry)
Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
NRG BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
SWOG S1418: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
Roche WO40181: A phase II, multicenter, randomized study to compare the efficacy of Venetoclax plus Fulvestrant Vs. Fulvestrant alone in women with ER positive HER2-negaitve locally advanced or metastatic breast cancer, who experienced disease recurrence or progression during or after CDK4/6 inhibitor therapy.
Astrazeneca D5336C00001: A Phase II, Open label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-related Genes (including BRCA1/2) (VIOLETTE)
Amgen 20170596: An Open-label Phase2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
RTOG 0924: A Phase III Randomized Trail: Androgen deprivation therapy and high dose radiotherapy with or without whole pelvic radiotherapy in unfavorable high risk Prostate Cancer
Celgene CONNECT MM: The Multiple Myeloma Disease Registry
Agendia FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
BMS CA209-234: Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Amgen 20070782: A randomized, double-blind, placebo-controlled study to evaluate the long-term safety and efficacy of Darbepoetin Alfa administered at 500ug once-every three weeks in anemic subjects with advanced stage Non-Small Cell Lung Cancer (NSCLC) receiving multi-cycle chemotherapy.
Amgen 20170758: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN
For more information and referral, please click here to contact us or call: (760) 416-4736
Note: Trials listed are currently recruiting unless otherwise noted. Recruiting status for trials may change or new trials may be available. Please call for updates.